Compare Stocks → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALDXNASDAQ:CHMANASDAQ:KALVNASDAQ:SBBPNASDAQ:TLC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$3.93-0.3%$3.64$1.42▼$11.97$233.48M1.51580,156 shs267,776 shsCHMAChiasma$3.76$4.01$2.77▼$5.74$217.68M1.282.12 million shs147 shsKALVKalVista Pharmaceuticals$10.78+2.8%$12.36$7.21▼$16.88$454.81M0.88719,135 shs241,417 shsSBBPStrongbridge Biopharma$2.00$2.09$1.85▼$4.26$135.66M1.58866,464 shs684,684 shsTLCTaiwan Liposome$7.00$7.10$4.07▼$7.70$294.54M0.99133,095 shs12,421 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics0.00%-1.01%+34.93%+29.61%-56.56%CHMAChiasma0.00%0.00%0.00%0.00%0.00%KALVKalVista Pharmaceuticals+1.35%-8.78%-5.58%-21.54%+31.13%SBBPStrongbridge Biopharma0.00%0.00%0.00%0.00%0.00%TLCTaiwan Liposome0.00%0.00%0.00%0.00%0.00%Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALDXAldeyra Therapeutics1.8978 of 5 stars3.52.00.00.02.42.50.0CHMAChiasmaN/AN/AN/AN/AN/AN/AN/AN/AKALVKalVista Pharmaceuticals4.0246 of 5 stars3.51.00.04.62.62.50.6SBBPStrongbridge BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ATLCTaiwan LiposomeN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics3.00Buy$9.33137.49% UpsideCHMAChiasmaN/AN/AN/AN/AKALVKalVista Pharmaceuticals3.00Buy$26.33144.28% UpsideSBBPStrongbridge BiopharmaN/AN/AN/AN/ATLCTaiwan LiposomeN/AN/AN/AN/ACurrent Analyst RatingsLatest CHMA, KALV, ALDX, TLC, and SBBP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.004/3/2024ALDXAldeyra TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$10.004/2/2024ALDXAldeyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.002/14/2024KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $24.002/13/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $35.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$2.04 per shareN/ACHMAChiasma$1.11M196.11N/AN/A$1.59 per share2.36KALVKalVista PharmaceuticalsN/AN/AN/AN/A$4.71 per shareN/ASBBPStrongbridge Biopharma$30.73M4.41N/AN/A$0.98 per share2.04TLCTaiwan Liposome$3.63M81.14N/AN/A$0.83 per share8.43Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$37.54M-$0.64N/AN/AN/AN/A-29.45%-24.24%5/2/2024 (Estimated)CHMAChiasma-$74.78M-$1.43N/AN/AN/AN/A-113.57%-57.62%N/AKALVKalVista Pharmaceuticals-$92.91M-$3.15N/AN/AN/AN/A-86.06%-72.65%7/5/2024 (Estimated)SBBPStrongbridge Biopharma-$45.08M-$0.78N/AN/AN/A-115.67%-66.82%-36.21%N/ATLCTaiwan Liposome-$35.02M-$0.88N/AN/AN/A-299.27%-120.45%-55.11%N/ALatest CHMA, KALV, ALDX, TLC, and SBBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/11/2024Q3 2024KALVKalVista Pharmaceuticals-$0.75-$0.84-$0.09-$0.84N/AN/A3/7/2024Q4 2023ALDXAldeyra Therapeutics-$0.21-$0.08+$0.13-$0.08N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/ACHMAChiasmaN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/ATLCTaiwan LiposomeN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A6.646.64CHMAChiasmaN/A7.917.08KALVKalVista PharmaceuticalsN/A5.445.44SBBPStrongbridge Biopharma0.383.002.95TLCTaiwan Liposome0.673.013.01OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%CHMAChiasma61.68%KALVKalVista PharmaceuticalsN/ASBBPStrongbridge Biopharma52.03%TLCTaiwan Liposome0.22%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics7.30%CHMAChiasma8.30%KALVKalVista Pharmaceuticals12.30%SBBPStrongbridge Biopharma5.10%TLCTaiwan LiposomeN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1559.41 million55.08 millionOptionableCHMAChiasma8557.89 millionN/ANot OptionableKALVKalVista Pharmaceuticals11842.19 million37.00 millionOptionableSBBPStrongbridge Biopharma7267.83 millionN/AOptionableTLCTaiwan Liposome2,02042.08 millionN/ANot OptionableCHMA, KALV, ALDX, TLC, and SBBP HeadlinesSourceHeadlineBack for More! TLC’s ‘MILF Manor’ Returns for Season 2: Meet the Cast Ahead of the Premiere Dateyahoo.com - April 26 at 5:11 PMAngela Deem accuses TLC of forcing her to 'keep her mouth shut' in unhinged rantmsn.com - April 23 at 11:14 PMHow to watch TLC’s ‘Little People, Big World’ new episodes free April 23masslive.com - April 23 at 6:13 PMWhy Kody Brown is the Most Disliked TLC Villain of All Timeyahoo.com - April 21 at 12:36 PM'I end up pooping myself on stage,' man cries after botched weight loss surgery in new TLC showmsn.com - April 19 at 10:23 AM‘7 Little Johnstons’ Season 14: How to watch episode 6 on TLC for freemsn.com - April 16 at 7:23 PMMonday: ‘Seeking Sister Wife’ Season 5, episode 7: How to watch TLC online for freecleveland.com - April 15 at 7:49 PMSee inside three-bed end terrace on sale for just £35k, but it needs serious TLCmsn.com - April 15 at 9:47 AMThe Disco Biscuits Nod To OutKast, TLC, Gucci Mane, & More In Atlanta [Video/Audio]liveforlivemusic.com - April 14 at 6:18 PMRico Wade, legendary Atlanta producer who worked with OutKast and co-wrote TLC's 'Waterfalls,' dies at 52msn.com - April 13 at 8:27 PMRico Wade, TLC ‘Waterfalls’ Cowriter and Southern Rap Trailblazer, Dies at 52thewrap.com - April 13 at 3:27 PMMorris continues new Brooks-TLC pleaobservertoday.com - April 12 at 8:34 AMTLC starts $27m upgradeaustralianageingagenda.com.au - April 11 at 8:17 PMTLC donates to Clatsop Animal Assistancedailyastorian.com - April 11 at 10:16 AMTLC Should Cancel ‘Sister Wives’ After Garrison Brown’s Suicidemsn.com - April 10 at 6:46 PMHow to watch TLC’s ‘Take My Tumor’ season 1, episode 2, stream for freepennlive.com - April 10 at 1:45 PMCrimestoppers seek tips on $500+ equipment theft from TLC Tree Service in Pananewschannel20.com - April 9 at 3:11 PM‘Seeking Sister Wife’ Season 5, episode 6: How to watch TLC online for freecleveland.com - April 8 at 7:40 PMHow to watch TLC’s ‘Seeking Sister Wife’ new episode free Monday, April 8masslive.com - April 8 at 7:40 PM'OutDaughtered' and 'Doubling Down With the Derricos' Finally Returning to TLC—See the Exclusive Teasersmsn.com - April 8 at 2:39 PMTLC is coming to the 2024 Wisconsin State Fair, with Jordin Sparks opening the concertmsn.com - April 8 at 2:39 PMFans Rejoice as ‘OutDaughtered’ and ‘Doubling Down With the Derricos’ Set to Premiere New Seasons on TLCmsn.com - April 8 at 2:39 PM2024 Wisconsin State Fair: TLC takes Main Stageyahoo.com - April 8 at 9:39 AM2024 Wisconsin State Fair: TLC takes Main Stage, Aug. 2fox6now.com - April 8 at 9:39 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAldeyra TherapeuticsNASDAQ:ALDXAldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.ChiasmaNASDAQ:CHMAChiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.KalVista PharmaceuticalsNASDAQ:KALVKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.Strongbridge BiopharmaNASDAQ:SBBPStrongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.Taiwan LiposomeNASDAQ:TLCTaiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.